Nancy Kemeny

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    N Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 13:1490-6. 2002
  2. pmc Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:3465-71. 2009
  3. doi request reprint Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
    N Kemeny
    Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
    Ann Oncol 20:1236-41. 2009
  4. ncbi request reprint The management of resectable and unresectable liver metastases from colorectal cancer
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    Curr Opin Oncol 22:364-73. 2010
  5. ncbi request reprint Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer
    Nancy Kemeny
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:4888-96. 2005
  6. ncbi request reprint Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer
    Nancy Kemeny
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4753-61. 2004
  7. ncbi request reprint Management of liver metastases from colorectal cancer
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncology (Williston Park) 20:1161-76, 1179; discussion 1179-80, 1185-6. 2006
  8. ncbi request reprint Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1395-403. 2006
  9. ncbi request reprint Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Surg Oncol 91:97-101. 2005
  10. doi request reprint Implanted hepatic arterial infusion pumps
    Margaret K Callahan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Cancer J 16:142-9. 2010

Detail Information

Publications77

  1. ncbi request reprint Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    N Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 13:1490-6. 2002
    ..Oxaliplatin exerts its antineoplastic activity through the formation of platinum-DNA adducts. Resistance to oxaliplatin is through repair of these adducts, which is inhibited by irinotecan...
  2. pmc Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:3465-71. 2009
    ..Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability...
  3. doi request reprint Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
    N Kemeny
    Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
    Ann Oncol 20:1236-41. 2009
    ....
  4. ncbi request reprint The management of resectable and unresectable liver metastases from colorectal cancer
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    Curr Opin Oncol 22:364-73. 2010
    ..To discuss when and who should get liver resection, how to get to resection and what treatments are useful in the pre or postoperative setting...
  5. ncbi request reprint Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer
    Nancy Kemeny
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:4888-96. 2005
    ..To determine the maximum-tolerated dose (MTD) of concurrent systemic oxaliplatin (Oxal) combinations plus hepatic arterial infusion (HAI) in patients with unresectable hepatic metastases from colorectal cancer...
  6. ncbi request reprint Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer
    Nancy Kemeny
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4753-61. 2004
    ..This multicenter study evaluated FU/LV with or without oxaliplatin in patients with metastatic CRC after disease progression on sequential fluoropyrimidine and irinotecan...
  7. ncbi request reprint Management of liver metastases from colorectal cancer
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncology (Williston Park) 20:1161-76, 1179; discussion 1179-80, 1185-6. 2006
    ..This review considers the timing and sequence of chemotherapy and surgery in this setting, as well as the roles of cryoablation, radiofrequency ablation, and radiation therapy...
  8. ncbi request reprint Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1395-403. 2006
    ..Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome...
  9. ncbi request reprint Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Surg Oncol 91:97-101. 2005
    ..Based on these data, we performed a phase II trial of hepatic arterial infusion (HAI) of FUDR and Dexamethasone (Dex) plus high-dose Mit-C for patients with unresectable hepatic metastases from colorectal carcinoma...
  10. doi request reprint Implanted hepatic arterial infusion pumps
    Margaret K Callahan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Cancer J 16:142-9. 2010
    ....
  11. ncbi request reprint Hepatic-arterial chemotherapy
    N Kemeny
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10021, USA
    Lancet Oncol 2:418-28. 2001
    ..We discuss the phase II and phase III studies of hepatic-arterial infusion therapy, with a focus on liver metastases from colorectal cancer...
  12. pmc Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
    J Clin Oncol 29:884-9. 2011
    ..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)...
  13. doi request reprint Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy
    Catha Fischer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    JAMA Surg 148:1103-8. 2013
    ..Portal vein embolization improves the safety of liver resection by increasing the size of residual liver, but the embolization may increase tumor growth during the waiting period before definitive hepatectomy...
  14. doi request reprint Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience
    Patrick S Wolf
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Am Coll Surg 216:41-9. 2013
    ..This study investigates the effect of preoperative chemotherapy for CRCLM on nontumoral liver histology and perioperative outcomes in a contemporary cohort...
  15. ncbi request reprint Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy
    Waldemar F Carlo
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Surg Oncol 87:85-90. 2004
    ..This article will address the question of whether large hepatic resections resulting in a greater loss of healthy liver predisposes patients to developing toxicity from the subsequent chemotherapeutic regimens...
  16. doi request reprint Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases
    David J Gallagher
    Department of Medicine, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA
    Ann Surg Oncol 16:1844-51. 2009
    ..We investigated the relation between response to neoadjuvant chemotherapy and overall survival (OS) in patients with colorectal liver metastases (CLM)...
  17. ncbi request reprint Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer
    Raphael Araujo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:4312-21. 2013
    ..Whether to administer chemotherapy as perioperative or adjuvant therapy remains controversial. We analyzed outcomes between these two treatment strategies...
  18. pmc Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis
    Marcus C B Tan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    HPB (Oxford) 15:803-13. 2013
    ..This study analyses how the prognostic capability of these variables changes in a conditional survival model...
  19. ncbi request reprint Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:3296-302. 2005
    ..The clinical evaluation of Drg1 in colorectal cancer has been limited. We performed this study to evaluate the role of Drg1 in a large cohort of patients with metastatic colorectal cancer who were irinotecan naive...
  20. ncbi request reprint Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
    ..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection...
  21. ncbi request reprint Presurgical chemotherapy in patients being considered for liver resection
    Nancy Kemeny
    Memorial Sloan Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10021, USA
    Oncologist 12:825-39. 2007
    ..The challenge for the future is to develop a multidisciplinary team approach that can design the best treatment plan for patients with liver metastases...
  22. ncbi request reprint Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases
    Peter J Allen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Gastrointest Surg 7:109-15; discussion 116-7. 2003
    ....
  23. ncbi request reprint Actual 10-year survival after resection of colorectal liver metastases defines cure
    James S Tomlinson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4575-80. 2007
    ..There is now sufficient follow-up on a significant number of patients to address the curative intent of resecting CLM...
  24. pmc A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer
    Yuman Fong
    1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Mol Ther 17:389-94. 2009
    ..During follow-up, no signs of virus reactivation were found. Multimutated HSV can be delivered safely into the human bloodstream to produce selective infection of tumor tissues and biologic effects...
  25. ncbi request reprint Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
    Mithat Gonen
    Departments of Epidemiology and Biostatistics, Medicine, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:406-12. 2003
    ....
  26. doi request reprint Metastatic colorectal cancer: from improved survival to potential cure
    David J Gallagher
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Oncology 78:237-48. 2010
    ..Better therapies have resulted in prolonged median survival for patients with metastatic disease and a select number of patients can now be cured...
  27. ncbi request reprint Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer
    N Kemeny
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3303-9. 2003
    ..The purpose of this study was to determine the maximum-tolerated dose (MTD) of systemic irinotecan (CPT-11) and HAI floxuridine (FUDR) plus dexamethasone (DEX) as combination adjuvant therapy after liver resection...
  28. doi request reprint Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases
    Celina Ang
    Department of Medicine, Gastrointestinal Oncology Service, NY, USA
    Breast J 19:96-9. 2013
    ..HAI and systemic chemotherapy is feasible and can benefit selected patients with BCLM, who have progressed on prior therapies. Patients require close monitoring for treatment-limiting toxicities...
  29. doi request reprint Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 248:84-96. 2008
    ..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort...
  30. doi request reprint A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies
    Archie N Tse
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Chemother Pharmacol 64:935-44. 2009
    ..To determine the maximum tolerated dose and duration of hepatic arterial infusion (HAI) gemcitabine in patients with unresectable hepatic metastases from colorectal cancer or primary hepatic malignancies...
  31. ncbi request reprint Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases
    Peter J Allen
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY10021, USA
    J Am Coll Surg 201:57-65. 2005
    ..Successful use of a hepatic arterial infusion pump requires a low technical complication rate. We evaluated the complications and longterm durability of these devices at our institution...
  32. ncbi request reprint Arterial embolization for salvage of hepatic artery infusion pumps
    Constantinos T Sofocleous
    Division of Interventional Radiology and Image Guided Therapies, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    J Vasc Interv Radiol 17:801-6. 2006
    ..The purpose of this study is to report experience in salvaging HAIPs with arterial embolization...
  33. ncbi request reprint Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver
    Nancy Kemeny
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Gene Ther 17:1214-24. 2006
    ..We conclude that NV1020, a genetically engineered but replication-competent HSV-1 oncolytic virus, can be safely administered into the hepatic artery without significant effects on normal liver function...
  34. ncbi request reprint Treatment of patients with colorectal cancer: emphasis on liver metastases
    David Gallagher
    Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Pharmacother 10:109-24. 2009
    ..In this review, we highlight the developments that have improved survival for patients with colorectal liver metastases and discuss the many issues that challenge further progress...
  35. ncbi request reprint Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver
    Ki Young Chung
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Radiat Oncol 15:284-98. 2005
    ..Therefore, the regional approach for hepatobiliary tumors deserves further investigation as well as randomized trials for adequate comparison to new systemic chemotherapies...
  36. doi request reprint KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:572-8. 2010
    ..To examine more directly whether KRAS mutations are associated with accelerated metastatic progression, we evaluated KRAS mutation as well as Ki-67 expression in patients with colorectal liver metastases not treated with cetuximab...
  37. ncbi request reprint Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Anticancer Drugs 15:219-27. 2004
    ..0 mg/m, with manageable toxicity. This combination shows encouraging activity, and survival appears promising in the pre-treated aCRC patient population. Further clinical trials are warranted...
  38. ncbi request reprint Gemcitabine-related radiation recall preferentially involves internal tissue and organs
    Philip A Friedlander
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:1793-9. 2004
    ..The development of internal tissue inflammation is reportedly correlated with a shorter interval from the time of completion of radiation therapy to the initiation of chemotherapy...
  39. ncbi request reprint Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors
    Jeremy Kortmansky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1875-84. 2005
    ..We designed a phase I clinical trial of FU in combination with UCN-01...
  40. ncbi request reprint Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer
    N Kemeny
    Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2687-95. 2001
    ..Although the main objective of this study was to evaluate the toxicity of the combined regimen, a high response rate (74%) was observed...
  41. ncbi request reprint Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer
    David J Gallagher
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Colorectal Cancer 8:172-4. 2009
    ..This case highlights an important cause of a falsely elevated CEA with abnormal PET imaging...
  42. ncbi request reprint A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans...
  43. ncbi request reprint Molecular therapies for colorectal cancer metastatic to the liver
    Philipp Mayer-Kuckuk
    Program of Molecular Pharmacology and Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 5:492-500. 2002
    ..Here we review molecular therapies for colorectal cancer metastatic to the liver...
  44. ncbi request reprint Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks
    S Sharma
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:3963-70. 2001
    ..In conclusion, the recommended Phase II dose for DX-8951f administered as a weekly 24-h infusion on a 3-of-4 week schedule is 0.8 mg/m(2) in minimally pretreated patients and 0.53 mg/m(2) in patients who are heavily pretreated...
  45. pmc Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 20:1589-95. 2009
    ....
  46. ncbi request reprint Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
    L B Saltz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3858-65. 1998
    ..In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these agents to maximize the potential for synergistic interaction...
  47. ncbi request reprint A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
    S Sharma
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 11201, USA
    Ann Oncol 13:1067-71. 2002
    ..ras genes encode Ras proteins that are important for signal transduction in cancer cells. Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras...
  48. ncbi request reprint Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis
    D J Gallagher
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Oncol 18:1995-9. 2007
    ..Response rates to systemic chemotherapy are low after tumor progression on oxaliplatin regimens. Hepatic arterial infusion (HAI) therapy in patients with tumor progression is a viable alternative...
  49. pmc Comparative genomic analysis of primary versus metastatic colorectal carcinomas
    Efsevia Vakiani
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 30:2956-62. 2012
    ..To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites...
  50. doi request reprint Second-line management of metastatic colorectal cancer
    David J Gallagher
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 7:25-32. 2008
    ..This article reviews treatment options after progression on irinotecan- or oxaliplatin-based first-line therapy and highlights some of the difficulties encountered when interpreting data...
  51. doi request reprint Improving response and outcomes for patients with liver-limited metastatic colorectal cancer
    David J Gallagher
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 9:S36-43. 2010
    ..In this article we discuss the biology of colorectal cancer metastases, the rationale for perioperative chemotherapy, and the recent and ongoing investigation of perioperative chemotherapy in the management of CLM...
  52. pmc CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Sergey V Shmelkov
    Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:2111-20. 2008
    ....
  53. ncbi request reprint A phase II trial of streptozotocin and adriamycin in advanced APUD tumors
    J Frame
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York
    Am J Clin Oncol 11:490-5. 1988
    ..With this dose and schedule of administration, STZ and Adriamycin produce modest response rates with objective palliation of disease in patients with advanced amine precursor uptake and decarboxylation (APUD) tumors...
  54. ncbi request reprint Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma
    N Kemeny
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021
    Am J Clin Oncol 11:66-72. 1988
    ..017). As a result, patient accrual continued. Problems encountered with the implementation of the group sequential methodology and the importance of stratification for prognostic variables are discussed...
  55. doi request reprint The role of floxuridine in metastatic liver disease
    Derek G Power
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Mol Cancer Ther 8:1015-25. 2009
    ..The high hepatic extraction of FUDR limits systemic side effects. Toxicity includes biliary and gastrointestinal ulcers...
  56. ncbi request reprint Phase I study of anticolon cancer humanized antibody A33
    Sydney Welt
    Department of Medicine at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:1338-46. 2003
    ..The present study was designed to (a) define the toxicities and maximum tolerated dose of huA33 and (b) determine huA33 immunogenicity...
  57. ncbi request reprint Intrahepatic arterial infusion of chemotherapy: clinical results
    Don S Dizon
    Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 29:126-35. 2002
    ..Current research is underway to improve the rate of extrahepatic metastases in patients undergoing HAI...
  58. ncbi request reprint Hepatic arterial infusion after liver resection
    Nancy E Kemeny
    N Engl J Med 352:734-5. 2005
  59. ncbi request reprint Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:954-60. 2002
    ..We have reviewed stage IV rectal cancer patients to evaluate the effectiveness of radical surgery without radiation as local therapy...
  60. ncbi request reprint Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer
    Sydney Welt
    Department of Medicine at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:1347-53. 2003
    ....
  61. ncbi request reprint Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:2904-11. 2003
    ....
  62. ncbi request reprint Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer
    Ronan J Kelly
    Waterford Regional Hospital, Ardkeen, Waterford, Ireland
    Clin Colorectal Cancer 5:166-74. 2005
    ..Continued progress in the field of HAI therapy may reduce the morbidity and mortality associated with CRC, so continued research in this area should be encouraged...
  63. ncbi request reprint Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases
    Gregory D Leonard
    Old School of Nursing, Waterford Regional Hospital, Waterford, Ireland
    Dis Colon Rectum 49:407-10. 2006
    ..These patients also confirm the importance of continued investigation of fluorouracil modulating agents, which may further enhance the recent progress made with fluorouracil-based combination chemotherapy for colorectal cancer...
  64. ncbi request reprint Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  65. ncbi request reprint Persistent CEA elevation in a patient with psoriasis and a history of metastatic colorectal cancer with no evidence of residual tumor
    Gregory D Leonard
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dig Dis Sci 49:1652-3. 2004
  66. ncbi request reprint Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 205:231-8. 2007
    ..But the benefits of resection and appropriate selection criteria in patients who develop both hepatic and pulmonary metastases are ill defined...
  67. ncbi request reprint Systemic or regional chemotherapy for liver metastases from colorectal cancer: has the wheel stopped spinning?
    J R Zalcberg
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Cancer J 10:271-9. 2004
    ....
  68. ncbi request reprint Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
    Leonard B Saltz
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4557-61. 2007
    ..We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer...
  69. ncbi request reprint Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
    Alon Scope
    Dermatology Service and Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
    J Clin Oncol 25:5390-6. 2007
    ..To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy...
  70. doi request reprint Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases
    Anne M Covey
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 247:451-5. 2008
    ....
  71. doi request reprint Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases
    Rebekah R White
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Surg Oncol 97:601-4. 2008
    ..The purpose of this retrospective analysis was to evaluate time to maximal response in patients receiving systemic +/- hepatic arterial infusion (HAI) chemotherapy alone for the treatment of CLM...
  72. doi request reprint Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer
    Hiromichi Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 247:994-1002. 2008
    ..The objective of this study was to evaluate the impact of postoperative morbidity on the long-term outcome after liver resection for MCRC...
  73. doi request reprint Advances in neoadjuvant therapy for colorectal cancer with liver metastases
    Carmelo Pozzo
    Unit of Medical Oncology, Department of Internal Medicine, Universita Cattolica del Sacro Cuore, Policlinico Universitario A Gemelli, Largo Agostino Gemelli, 8, 00168 Rome, Italy
    Cancer Treat Rev 34:293-301. 2008
    ..These trials must include well-defined criteria for resectability and clear reporting of the extent of resection...
  74. doi request reprint Regional chemotherapy for liver-limited metastatic colorectal cancer
    Derek G Power
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Colorectal Cancer 7:247-59. 2008
    ..The role of HAI therapy for the treatment of unresectable and resectable disease, as well as the use of other regional strategies such as embolization and ablation, are discussed...
  75. ncbi request reprint Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification
    Marian Iwamoto
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Biol Ther 3:395-9. 2004
    ..In as much as TS is transcriptionally regulated by E2F-1, these results provide an explanation for the high levels of TS mRNA noted in some tumor samples...
  76. ncbi request reprint An update on hepatic arterial infusion chemotherapy for colorectal cancer
    Adam D Cohen
    Gastrointestinal Oncology Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncologist 8:553-66. 2003
    ..In an attempt to prevent extrahepatic progression, combinations of HAI with systemic chemotherapy, including newer agents such as irinotecan and oxaliplatin, are currently being investigated, with promising early results...
  77. ncbi request reprint Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma
    Gregory D Leonard
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2038-48. 2005
    ..This review summarizes the current data on neoadjuvant chemotherapy, the rationale for this approach, potential complications, and future prospects...

Research Grants9

  1. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 1999
    ..Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible. ..
  2. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 1993
    ..FUR has a high hepatic extraction; we will test teroxirone extraction. both drugs are effective against colon cancer cell lines (Bertino - I-R01)...
  3. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 2000
    ..Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible. ..
  4. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 2001
    ..Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible. ..